Pediatric Endocrinology and Diabetology | Gabor Szinnai

Ce contenu est disponible uniquement en anglais.

Over the last two years projects have been realized with local, national and international collaborators in Endocrinology and Diabetology. Further, as a result of strong partnership with Pediatric Pharmacology UKBB (Prof Pfister) the digital health project OptiThyDose was granted by BRCCH in 2022 (https://brc.ch/research/optithydose/).

Diabetology

First, the DiaHEART study, in teamwork with Prof Donner, Pediatric Cardiology UKBB, is described in detail in Autonomic cardiac regulation during nocturnal hypoglycemia in diabetic children (Pediatr Diabetes 2021). Second, a comprehensive quality of life study describes the psychosocial burden and fear of hypoglycemia in parents and their children with type 1 diabetes (Front Endocrinol 2022). Finally, the DiaCAMP and DiaMONITOR studies combining continuous parallel measurement of physical activity and heart rate with routine glucose sensor data over 7 days have been realized. The aim of these studies is to develop personalized recommendations to predict and avoid hypoglycemia in children with type 1 diabetes. These data are currently being analyzed in collaboration with Pediatric Pharmacology UKBB (Prof Pfister), Computer Science and Machine Learning ETH Zürich (Prof Vogt), and Computational Systems Biology ETH Zürich (Dr Kaltenbach).

Endocrinology

Based on retrospective longitudinal clinical data from four pediatric centers (Basel, Zürich, St.Gallen, Bern) we developed with the teams of Pediatric Pharmacology UKBB (Prof Pfister) and Department of Mathematics, University of Konstanz (Prof Schropp), algorithms for optimal personalized dosing for neonates with congenital hypothyroidism and children with hyperthyroidism (JPKPD 2021, J Optim Theory Appl 2021). As a next step, clinical validation of these algorithms is planned in the context of the BRCCH-granted OptiThyDose study together with Prof Pfister’s and Prof Schroppp’s teams. The OptiThyDose study is designed as a large multicenter prospective randomized controlled trial. Participating clinical partners are Hôpital Necker, Paris (Prof Polak), Ospedale Bambino Gesù, Rome (Prof Cappa) and Arabkir Medical Center in Yerewan, Armenia (Prof Navasardyan). The ultimate aim is to provide simple personalized dosing to children with thyroid diseases.